<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03178370</url>
  </required_header>
  <id_info>
    <org_study_id>13.0890</org_study_id>
    <nct_id>NCT03178370</nct_id>
  </id_info>
  <brief_title>Gastroparesis Syndromes: Pathophysiology and Response to Electrical Stimulation</brief_title>
  <official_title>Autonomic Dysregulation and Enteric Nerve Changes in the Pathophysiology of Diabetic Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autonomic, inflammatory, enteric, electrophysiologic and hormonal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were evaluated by two methods in each of five areas: inflammatory, autonomic,
      enteric, electrophysiologic, and hormonal.

      In part one, patients had similar GI Symptoms regardless of baseline gastric emptying or
      diabetic/non-diabetic status and all patients demonstrated abnormalities in each of the 5
      areas studied.

      In part two, patients showed early and late effects of electrical stimulation with changes
      noted in multiple areas, categorized by improvement status.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 6, 2014</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal symptoms</measure>
    <time_frame>Change from baseline to 6 days to 6 months</time_frame>
    <description>By standardized symptom scoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastric Emptying Test</measure>
    <time_frame>baseline, 6 days, 6 months</time_frame>
    <description>By gastric emptying test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic</measure>
    <time_frame>Change from baseline to 6 days to 6 months</time_frame>
    <description>By autonomic function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormones</measure>
    <time_frame>Change from baseline to 6 days to 6 months</time_frame>
    <description>By serum measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>Change from baseline to 6 days to 6 months</time_frame>
    <description>By serum measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying</measure>
    <time_frame>baseline, 6 days, 6 months</time_frame>
    <description>By radionuclides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrophysiology</measure>
    <time_frame>Change from baseline to 6 days to 6 months</time_frame>
    <description>By Electrogastrogram(EGG)/ Electrogram (EG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Change from baseline to 6 days to 6 months</time_frame>
    <description>By standardized scale</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">43</enrollment>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Diabetic Gastroparesis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Idiopathic Gastroparesis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gastric Electrical Stimulation</intervention_name>
    <description>Temporary and permanent gastric electrical stimulation</description>
    <arm_group_label>Diabetic Gastroparesis</arm_group_label>
    <arm_group_label>Idiopathic Gastroparesis</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        From 44 consecutive consented patients seen in our clinic, 43 were deemed to be eligible
        for the study. Those 43 patients were the basis for the baseline evaluation (part one) of
        this study. Of 43 patients, (description: 15 M, 28 F, mean age 46.3 years; 23 DM, 20 ID),
        41 (description: 13 M, 28 F, mean age 45.7 years; 21 DM, 20 ID), finished the temporary
        phase of gastric electrical stimulation, and 36 (description: 11 M, 25 F, mean age 44.7
        years; 18 DM, 18 ID) of those 41 were implanted with permanent GES devices. Of 36
        implanted, 30 patients (description: 9 M, 21 F, mean age 43.1 years; 14 DM, 16 ID) were
        followed at 6 months. The entirety of the GES patients, baseline, temporary and permanent,
        were the basis for the stimulation portion (part two) of this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willingness to participate in study and sign informed consent.

          2. Age 18 or older.

          3. Symptoms of gastroparesis for at least 6 months.

          4. Refractory or intolerant to antiemetic drugs.

          5. Refractory or intolerant to prokinetic drugs.

          6. If Diabetic, documentation of medication for diabetes for at least 6 months.

          7. No evidence of anatomic obstruction of GI tract. -

        Exclusion Criteria:

          1. Previous gastric surgery.

          2. History or evidence of rumination syndrome, eating disorder of primary psychiatric
             disorder.

          3. No know collagen vascular disease.

          4. Inability or unwillingness to participate in the study.

          5. Current active gastric stimulation or other gastrointestinal neurostimulation implant
             or device.

          6. Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2017</study_first_submitted>
  <study_first_submitted_qc>June 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2017</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Thomas Abell</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Gastroparesis</keyword>
  <keyword>Nausea and Vomiting</keyword>
  <keyword>Abdominal Pain</keyword>
  <keyword>Gastric Emptying</keyword>
  <keyword>Electrophysiology</keyword>
  <keyword>Hormones</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Enteric Nervous System</keyword>
  <keyword>Autonomic Nervous System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>No plan in place.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

